To Top

Community

David Alvaro, Ph.D.

David is Scientific Editorial Director for That’s Nice and the Pharma’s Almanac content enterprise, responsible for directing and generating industry, scientific and research-based content, including client-owned strategic content. Before joining That’s Nice, David served as a scientific editor for the multidisciplinary scientific journal Annals of the New York Academy of Sciences. He received a B.A. in Biology from New York University and a Ph.D. in Genetics and Development from Columbia University.

Contribution
Artificial Intelligence

Trump Signs Executive Order Launching the American AI Initiative

PAO-M02-19-NI-012
Oral Insulin

An Innovative Approach to Oral Insulin

PAO-M02-19-NI-010
Acquistion

Alexion Acquires Minority Stake in Caelum Biosciences

PAO-M02-19-NI-007
Diabetes

Novo Nordisk to Use Priority Voucher for Diabetes Drug

PAO-M02-19-NI-004
Cell and Gene Therapy

Massachusetts is Looking for Ways to Help Patients Receive Expensive Gene Therapy

PAO-M01-19-NI-022
Drug Development

Researchers Identify Potential Approach for Treating the Toughest Breast Cancer

PAO-M01-19-NI-013
Investment

Biotech Company Stealth BioTherapeutics Files for IPO

PAO-M01-19-NI-007
FDA Approval

FDA Approves Parkinson’s Drug

PAO-M01-19-NI-002
CRISPR

Gene Amplification Controls Obesity in Mice

PAO-M12-18-NI-018
Drug Development

AbbVie Exercises Option to License Parkinson’s Tech from BioArctic

PAO-M12-18-NI-015
Dementia

Single Gene Identified as Culprit in Early-Onset Dementia

PAO-M12-18-NI-016
Spin-off Business

Mallinckrodt Spins off its Generics Business

PAO-M12-18-NI-005-11
Acquisition

GSK Acquires Oncology Company Tesaro

PAO-M12-18-NI-008
Collaboration Agreement

Cilag GmbH to Collaborate with argenx on New Treatment for AML, MDS

PAO-M12-18-NI-005
FDA

First Treatment for Primary Hemophagocytic Lymphohistiocytosis Approved by FDA

PAO-M11-18-NI-027
FDA Approval

Novartis’ Promacta Gets Expanded Use Approval from the FDA

PAO-M11-18-NI-020
Drug Development

Novartis Grabs Attention for its Development Pipeline

PAO-M11-18-NI-011
RNAi

Eli Lilly, Dicerna to Collaborate on RNAi Drug Development

PAO-M11-18-NI-006
FDA Approval

Genentech Receives FDA Approval for Flu Medicine

PAO-M11-18-NI-001
Big Data

Big Data in Drug Development and Discovery

PAP-Q4-18-NI-006
Big Data

Big Data in Drug Manufacturing

PAP-Q4-18-NI-005
New Drug News

New Drug News: Regulatory Approval Brings siRNA into the Rare Disease Toolbox

PAP-Q4-18-NI-010
Patient Centric

Pursuing Patient Centricity from Start to Finish

PAP-Q3-18-NI-005
Patient Centric

Remember the User – Incorporating Patient Centricity into Drug Design

PAP-Q3-18-NI-006
Patient Centric

The Impact of Patients as Consumers: New Fill/Finish and Packaging Solutions

PAP-Q3-18-NI-007
Regulatory

Competitive Generic Therapy: A New Patient-Centric FDA Pathway

PAP-Q3-18-NI-008